Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients
Clin. transl. oncol. (Print)
; 15(7): 582-586, jul. 2013. tab, ilus
Article
en En
| IBECS
| ID: ibc-127472
Biblioteca responsable:
ES1.1
Ubicación: BNCS
ABSTRACT
BACKGROUND:
Currently, first-line chemotherapy in advanced colorectal cancer is not tailored on predictive biomarkers. Bax proapoptotic protein may correlate to chemosensitivity and differential response to irinotecan or oxaliplatin-based combinations.METHODS:
Bax expression was assessed by immunohistochemistry in 49 advanced colorectal cancer patients enrolled at our institution from 2002 to 2004 within a multicenter, phase II, randomized trial of first-line UFT/leucovorin/irinotecan (TEGAFIRI) versus UFT/leucovorin/oxaliplatin (TEGAFOX).RESULTS:
Bax-positive and negative samples were 49 and 51 %. Response was significantly lower in Bax positive (25 %) as compared to Bax negative (56 %) (Odds ratio = 0.26; p = 0.03). No significant difference was noted in TEGAFOX subgroup; in TEGAFIRI arm, responses were lower in Bax positive (18 %) than Bax negative (67 %) (Odds ratio = 0.11; p = 0.03). No difference in terms of progression-free and overall survival was observed according to Bax.CONCLUSION:
Bax-negative colorectal cancer may identify a specific phenotype of patients with significantly higher chance to respond to doublet irinotecan-based chemotherapy (AU)
Buscar en Google
Colección:
06-national
/
ES
Base de datos:
IBECS
Asunto principal:
Camptotecina
/
Neoplasias Colorrectales
/
Proteína X Asociada a bcl-2
/
Antineoplásicos
Tipo de estudio:
Clinical_trials
/
Risk_factors_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Clin. transl. oncol. (Print)
Año:
2013
Tipo del documento:
Article